Skip to: Curated Story Group 1
lifesciencesreview

Advertise

with us

  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Topics
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomarker
    Business Services
    Business Services
    Business Services
    Business Services
    Business Services
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Pharmacy Management
    Regulatory Services
    Technologies and Software
  • CXO Insights
  • Vendor Viewpoint
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • CXO Awards
AUGUST 2023LIFE SCIENCES REVIEW9The service needs between sponsors may significantly vary depending on many factors, but generally, there are some fundamental differences between emerging biotech versus large pharma companies. The smallest of emerging biotechs may have limited experience in clinical development, so a CRO can work extremely closely with them to provide consultations and guidance, in addition to providing the various specialists and experts needed for all aspects of clinical trial design and execution. A CRO can provide expanded capabilities to a small biotech, whereas a CRO can provide expanded capacities to a large pharma. A large pharma may already have experience and expertise in-house but is looking for experienced clinical research professionals to augment their own teams. Clinical trials often involve a very high number of team members, so CROs can offer scalability to Sponsors. The general rule of thumb is to select a CRO that is proportionately sized to the size of the sponsor company. That is, small companies work with small companies, and large with large. But that is not necessarily always true, as there are numerous factors for a Sponsor company to consider when selecting a CRO. CROs greatly vary in many ways, including size (i.e., small, midsized, large), geographical reach (i.e., having experience with regulatory authorities across different countries, local staff, and resources), therapeutic area expertise/focus (i.e., there are CROs that specialize in only oncology clinical trials), and development phase focus (i.e., early phase versus late phase). There are some CROs that are more niche and focus on certain limited aspects, and there are also large CROs that have the expertise to do it all. That is just a limited sample, but there are numerous factors for a Sponsor to consider when selecting a CRO. Ultimately, service cost is often an important consideration. But relevant expertise and experience and anticipated timelines are important factors. One less often mentioned factor is the proposed team that a potential CRO offers to a Sponsor, which can significantly vary even within a CRO (i.e., in terms of experience, communication, and collaboration style). Selecting a CRO is in some ways more like an art than a science for a sponsor, although when analyzed factor by factor, then weighing the importance of those factors, it often ultimately is clear which may appear to be the best CRO partner for a Sponsor at that time. The best way to arrive at that decision and conclusion is to have discussions and bids from multiple CROs, starting broadly and eventually narrowing down. CRO and sponsor partnerships are important in clinical development, and it is important for a sponsor to carefully select the best CRO for their exact needs. The general rule of thumb is to select a CRO that is proportionately sized to the size of the sponsor companyCRO AND SPONSOR PARTNERSHIPS IN CLINICAL DEVELOPMENT
< Page 8 | Page 10 >